38.72

2.25% -0.89

After Hours: 38.50 -0.22 -0.57%

Biohaven Ltd (BHVN)

Overview News Price History Option Chain Why BHVN Down? Discussions Forecast

Biohaven Ltd stock is currently priced at $38.72, with a 24-hour trading volume of 950.94K. It has seen a -2.25% decreased in the last 24 hours and a -30.67% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $40.25 pivot point. If it approaches the $38.61 support level, significant changes may occur.

Previous Close:

$39.61

Open:

$40.19

24h Volume:

950.94K

Market Cap:

$3.42B

Revenue:

Net Income/Loss:

$-408.17M

P/E Ratio:

-5.1834

EPS:

-7.47

Net Cash Flow:

$-334.77M

1W Performance:

-12.06%

1M Performance:

-30.67%

6M Performance:

+38.73%

1Y Performance:

+179.16%

1D Range:

$38.38

$40.62

52W Range:

$12.35

$62.21

Biohaven Ltd Stock (BHVN) Company Profile

Name

Biohaven Ltd

Sector

Healthcare (1200)

Industry

Biotechnology (685)

Phone

203-404-0410

Address

234 Church Street, New Haven, CT

Employee

Twitter

@biohavenpharma

Next Earnings Date

2022-11-07T13:30:00.000Z

Latest SEC Filings

BHVN's Discussions on Twitter

Biohaven Ltd Stock (BHVN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-16-24	Initiated	RBC Capital Mkts	Outperform
Feb-06-24	Initiated	UBS	Buy
Dec-22-23	Initiated	H.C. Wainwright	Buy
Dec-08-23	Initiated	Robert W. Baird	Outperform
Jan-24-23	Initiated	SVB Securities	Outperform
Jan-04-23	Initiated	JP Morgan	Overweight
Dec-02-22	Initiated	BTIG Research	Buy
Oct-26-22	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Oct-12-22	Initiated	Piper Sandler	Overweight
Aug-19-22	Downgrade	Piper Sandler	Overweight → Neutral
Aug-08-22	Downgrade	Wedbush	Outperform → Neutral
May-11-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Oct-19-21	Resumed	Morgan Stanley	Equal-Weight
Aug-10-21	Downgrade	UBS	Buy → Neutral
Aug-03-21	Reiterated	Canaccord Genuity	Buy
Mar-11-21	Initiated	UBS	Buy
Dec-15-20	Initiated	H.C. Wainwright	Buy
Apr-17-20	Initiated	Cowen	Outperform
Feb-10-20	Downgrade	Oppenheimer	Outperform → Perform
Feb-06-20	Initiated	Mizuho	Buy
Nov-22-19	Initiated	Wedbush	Outperform
Jun-25-19	Reiterated	Canaccord Genuity	Buy
May-06-19	Initiated	Goldman	Buy
Apr-09-19	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Mar-04-19	Reiterated	Needham	Buy
Jul-03-18	Reiterated	Needham	Buy
Jul-02-18	Reiterated	Needham	Buy
Apr-05-18	Downgrade	Barclays	Overweight → Equal Weight
Feb-22-18	Reiterated	Canaccord Genuity	Buy
Dec-15-17	Initiated	Canaccord Genuity	Buy
Oct-03-17	Reiterated	Needham	Buy

View All

Biohaven Ltd Stock (BHVN) Latest News

Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Benzinga

FedEx Posts Downbeat Earnings, Joins Steelcase, argenx And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Benzinga

Arcellx (ACLX) Up 5% on Partnership Expansion With Gilead

Zacks Investment Research

Biohaven Ltd Stock (BHVN) Financials Data

Biohaven Ltd (BHVN) Net Income 2024

BHVN net income (TTM) was -$408.17 million for the quarter ending December 31, 2023, a +28.43% increase year-over-year.

Biohaven Ltd (BHVN) Cash Flow 2024

BHVN recorded a free cash flow (TTM) of -$334.77 million for the quarter ending December 31, 2023, a +1.18% increase year-over-year.

Biohaven Ltd (BHVN) Earnings per Share 2024

BHVN earnings per share (TTM) was -$5.72 for the quarter ending December 31, 2023, a +57.64% growth year-over-year.

Biohaven Ltd Stock (BHVN) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
CHILDS JOHN W	Director	Apr 22 '24	Buy	41.00	195,121	7,999,961	4,096,512
Coric Vlad	Chief Executive Officer	Apr 22 '24	Buy	41.00	121,951	4,999,991	1,788,417
Bailey Gregory	Director	Apr 22 '24	Buy	41.00	48,780	1,999,980	1,574,568
Antonijevic Irina	Director	Dec 29 '23	Option Exercise	0.00	11,000	0	13,535
Antonijevic Irina	Director	Dec 29 '23	Sale	41.79	11,000	459,662	2,535
CHILDS JOHN W	Director	Oct 05 '23	Buy	22.00	454,545	9,999,990	3,998,952
Coric Vlad	Chief Executive Officer	Oct 05 '23	Buy	22.00	340,908	7,499,976	833,120
Coric Vlad	Chief Executive Officer	Oct 05 '23	Buy	22.00	113,637	2,500,014	1,657,031
Buten Matthew	Chief Financial Officer	Oct 05 '23	Buy	22.00	22,727	499,994	189,380
Bailey Gregory	Director	Oct 04 '23	Buy	22.57	17,817	402,094	1,525,788

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. Its lead product candidate is rimegepant, which is in Phase III clinical trials for the acute treatment of migraine. The company also develops trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia; and Phase II/III clinical trial for the treatment of obsessive compulsive disorders, as well as for the treatment of Alzheimer's diseases. In addition, it develops BHV-3500 for the acute treatment and prevention of migraine; BHV-0223 for the treatment of amyotrophic lateral sclerosis, a neurodegenerative disease that affects nerve cells in the brain and spinal cord; and BHV-5000 for the treatment of symptoms associated with Rett syndrome, such as breathing irregularities. The company was founded in 2013 and is based in New Haven, Connecticut. Biohaven Pharmaceutical Holding Company Ltd. is a subsidiary of Portage Biotech Inc.